Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.

Saved in:
Bibliographic Details
Title: Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.
Authors: Cooper CL; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Morrow G; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Yuan M; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Postler TS; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Neal ML; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA., Cross RW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA., Woolsey C; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA., Agans KN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA., Borisevich V; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA., McNamara RP; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA., Atyeo C; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA., Roy V; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA., Germosen D; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA., Hou F; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Li SL; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Reiserova L; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Choi Y; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Wilson A; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Wagner D; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Wallace-Selman O; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Carpov A; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Geng F; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Frederick DJ; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., DeStefano J; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Ercolini AM; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Enriquez AS; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Hastie KM; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Ramos da Silva S; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Sayeed E; IAVI, New York, NY 10004, USA., Coleman JW; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA., Kilianski A; IAVI, New York, NY 10004, USA., Alter G; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA., Saphire EO; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Aitchison JD; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; Departments of Pediatrics and Biochemistry, University of Washington, Seattle, WA 98109, USA., Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA., Gupta SB; IAVI, New York, NY 10004, USA., Feinberg MB; IAVI, New York, NY 10004, USA., Parks CL; IAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA. Electronic address: cparks@iavi.org.
Source: EBioMedicine [EBioMedicine] 2025 Apr; Vol. 114, pp. 105647. Date of Electronic Publication: 2025 Mar 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2025.105647